Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
Oncolytics Biotech discloses compelling new pelareorep combination data—in anal and pancreatic cancer cohorts—highlighting durable responses and tolerable safety …
Dogwood kicks off the Phase IIb study of Halneuron®, a non-opioid Nav1.7 inhibitor for chemotherapy-induced neuropathy—marking a critical …
The journal Nature identifies seven transformative technologies for 2025, with self-driving laboratories and advanced immunotherapies set to accelerate …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …
Already a subscriber? Log in